

March to a UNIVERSAL VACCINE...

Tar on their Heels... Blood on their hands

HIV Inc (1984)

Immunity
Shield
"The Act"

[1986]

AZT Patent
Challenge
Fails

(1991-1996)...
...and
expires

UNC Chapel Hill Begins Gain of Function (Weaponization)

of CoV for Vaccine
Platform

1996 - 1999



Fauci and Baric Make

Make

FrankenCoV...

...and patent it

1999 - 2002



THE UNIVERSITY

of NORTH CAROLINA
at CHAPEL HILL

1984...The Vaccine Nightmare... \$191 Billion Later...Burn the Village

- 1986 1999: HIV Vaccines fail on every trial
- 2001: Anthrax...Although production of an efficient anthrax vaccine is an ultimate goal, the benefits of vaccination can be expected only
 if a large proportion of the population at risk is immunized. https://www.govinfo.gov/content/pkg/FR-2020-02-21/pdf/2020-03444.pdf
- 2016: The AMP Study (UNC Chapel Hill) that just launched, HVTN 704/HPTN 085, will take place at 24 sites in Brazil, Peru and the United
 States, and will enroll 2,700 men and transgender people who have sex with men. https://www.niaid.nih.gov/news-events/nih-launches-large-clinical-trials-antibody-based-hiv-prevention
- 2018: Dr. Fauci outlined some of the challenges of seasonal and pandemic influenza, showing data for this influenza season in comparison to previous seasons and noting that NIAID has created a strategic plan for universal influenza vaccine research. https://www.niaid.nih.gov/about/niaid-council-minutes-january-29-2018
- 2019: Hepatitis C... Dr. Stanley Lemon, DMID Subcommittee member and professor of medicine, microbiology and immunology, University of North Carolina at Chapel Hill, provided an update on the state of HCV vaccine development. Dr. Lemon described various scientific and other challenges associated with developing HCV vaccines, for example, critical immune correlates of protection are not known, and clinical trials to assess vaccine efficacy are extremely daunting and lengthy, complicated by difficulty accessing at-risk populations. He outlined a compelling case for the need for an HCV vaccine, noting that HCV-related deaths have exceeded deaths from HIV/AIDS within the United States since 2007, and that the current opioid epidemic has profoundly altered the epidemiology of HCV, increasing the rates of new infection. He described current research activities and outlined a number of activities that could be pursued to accelerate HCV vaccine development efforts. niaid.nih.gov/about/niaid-council-minutes-january-28-2019

it is quite possible, in fact it's invariable, that we will develop a vaccine for AIDS.

He meant "inevitable"?

Nobody's Listening, Everybody Hates Me...I'm going to go make warmieapon

 "It is quite possible, in fact it is invariable, that we will develop a vaccine for AIDS"...epic fail

1984

• H5N1...Vaccine first, Tamiflu second...epic fai

 Influenza...Vaccine first, pleading with the public and Congress for years...epic fail 200

2019

SARS Reverse Genetics

Baric, Ralph

University of North Carolina Chapel Hill, Chapel Hill, NC, United States

Abstract

Severe acute respiratory syndrome is a life-threatening human illness characterized by mortality rates exceeding 50% in the elderly. The SARS coronavirus contains a approximately 30Kb single-stranded, positive polarity RNA genome. The availability of a full-length infectious cDNA of the SARS genome would not only provide complete genetic control over the virus, but allow for rational design of live viruses as candidate vaccines. Consequently, we believe that a SARS reverse genetic system must rank near the top of the priorities for controlling this important human pathogen. We are the only group in the US to have successfully assembled full-length infectious cDNAs of the coronaviruses, mouse hepatitis virus (MHV) and transmissible gastroenteritis virus (TGEV) and have demonstrated that these full length constructs provide novel opportunities for studying the genetics of coronavirus replication and pathogenesis. In aim 1, we will develop a full length SARS cDNA clone and compare the phenotype of rescued molecular cloned viruses with wildtype using biochemical assays and macaque challenge experiments.

In **Aim 2**, we will develop high titer SARS single hit replicons for use as expression vectors and vaccines.

That 3, we will select for SARS host range mutants that replicate in murine cells, identify the mechanism of SARS cross species transmission using reverse genetic approaches and evaluate the pathogenicity of these viruses in rodents and non human primates. The goal of this application is to establish genetic control over the SARS genome and provide uniform reagents that will be used by other groups throughout the country.

Funding Agency

Agency National Institute of Health (NIH)
Institute National Institute of Allergy and
Infectious Diseases (NIAID)

Type Research Project (R01)

Type Research Project (R01)
Project # 5R01AI059136-04


Application # 7174658
Study Section Virology Study Section (VR)

Program Officer Cassels, Frederick J

Project Start 2004-02-15 Project End 2009-01-31

Budget Start 2007-02-01 Budget End 2008-01-31

Support Year 4 Fiscal Year 2007 Total Cost \$276,869 Indirect Cost



50 What's Next?

- We PROSECUTE the criminals for:
 - Domestic Terrorism
 - Premeditated Murder
 - Biological Weapons
- We CANCEL the EUA:
 - Put '86 Act and PREP Act Liability on Pfizer, Moderna, J&J and NOVAVAX for criminal conspiracy
- We REVOKE NIAID, FDA, and CDC Funding immediately
 - Congress must reform '86 and PREP immunity shields to mandate conformity to ESTABLISHED clinical trials only

- Stop funding ANY LAWSUIT that stipulates "Vaccine"; "COVID-19"; "SARS CoV-2"
- Stop supporting individuals and organizations that don't collaborate on the criminal prosecution
- Honor the valiant contributions of those who have served... and who have been ignored by "personalities"

What YOU MUST DO

Paid 3

In the United States Courts

United States of America
Attorney General with a Conscience

V

Mr. Alex Azar, DEFENDANT
Dr. Anthony Fauci, DEFENDANT
Dr. Peter Daszak, DEFENDANT
Dr. Ralph Baric, DEFENDANT
FDA, DEFENDANT
CDC, DEFENDANT
NIAID, DEFENDANT
MODERNA, DEFENDANT
PFIZER, DEFENDANT

Count 1: 18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens

Count 2: 18 USC § 2339 – Conspiring to Commit Acts of Terrorism

Count 3. 15 U.S.C. §1-3 – conspiring to criminal commercial activity

Count 4. 18 USC § 175 – Funding and Creating a Biological Weapon

Count 5. <u>15 U.S.C. §8</u> – market manipulation and allocation

Count 6. 18 U.S.C. § 1001 - lying to Congress

Count 7. 15 U.S.C. § 19 – interlocking directorates

Count 8. 18 U.S. Code § 2384 - Seditious conspiracy

The Proposed Indictment

Throughout the decade of the 90s Pfizer sought to research, develop and patent a coronavirus (CoV) vaccine. Their first patent filing specifically recognizing the S-protein as the immunologic target for vaccines was filed on November 14, 1990 (U.S. Patent 6,372,224). With a focus on swine and canine gastroenteritis, these efforts showed little commercial promise and the patent was abandoned in April of 2000. During the same period, the

Download, Print, and Send to your Attorney General, your U.S. Attorney, and to all your elected officials

www.davidmartin.world

www.fullyliveacademy.com